New developments in the management of borderline resectable pancreatic cancer. Review uri icon

Overview

abstract

  • The optimal management of borderline resectable pancreatic cancer remains unclear. Neoadjuvant chemoradiation remains the most common approach in the United States, while neoadjuvant chemotherapy alone is also widely utilized and has demonstrated efficacy but there has been no clear consensus about a regimen that would be most beneficial in this setting. We will discuss three abstracts that were presented in the 2013 ASCO Gastrointestinal Cancers Symposium in which various regimens were evaluated in the neoadjuvant setting.

publication date

  • March 10, 2013

Research

keywords

  • Adenocarcinoma
  • Pancreatic Neoplasms

Identity

Scopus Document Identifier

  • 84875023786

Digital Object Identifier (DOI)

  • 10.6092/1590-8577/1473

PubMed ID

  • 23474551

Additional Document Info

volume

  • 14

issue

  • 2